In addition to rolling out its newly EU approved, highly accurate rapid swab to the Middle East, Gennecs, the leading company in the manufacture and development of innovative medicines and medical devices, revealed their successful signing of a number of exclusive contracts with two of the top-notch manufacturers of vaccines, serums, and biotech medicines in the world.
Additionally, the company announced their regional agency agreement for the Middle East, which shoulders the responsibility of launching the new Swiss-made swabs that are made to make Coronavirus tests much easier, timelier & cost effective. Currently, this swab is utilized in most of the major European countries. Thus, introducing this swab to the middle east markets, comes in light of supporting the medical sector in the Middle East region, as well as meeting the challenges of the second wave of the emerging Coronavirus pandemic.
To further explicate, this new swab test is deemed to be a breakthrough, and it is believed to be one of the most important and latest methods that science has reached in Europe. As mentioned before, this European swab is manufactured in Switzerland and has obtained the approval of registration and marketing authorization in Switzerland, France, Germany, Poland, and most of the European Union countries with full world class accreditation. It is also one of fastest methods to diagnose Coronavirus with an accuracy of up to 99% without laboratory intervention.
On that occasion, Dr. Nibal Dahaba, the Founding Partner and General Manager of the emerging markets region at Gennecs, commented: “Our goal at Gennecs is ensuring access to diagnosis, vaccination & treatment to each and every single patient, also one of our ongoing goals is basically attracting investments to our region with focus on biotech manufacturing in order to align with all global strategies ensuring no shortage when it comes to biotech products. In fact, we have seen the endeavors of the local political leadership who are keen in providing the latest up to date & state-of-the-art pharmaceutical production lines, making them one of the few worldwide pharmaceutical facilities in terms of machinery and technical specs.”
Dahaba has also added: “Gennecs is a multi-disciplinary holding company with an integrated experience in the cycle of pharmaceutical products, whether innovative ones or underlicenced ones in addition to medical devices, vaccines & serums from its manufacture and development right up to the marketing stage.
Christian Frealdsson, from the Swiss company, expressed his enthusiasm about the cooperation with Gennecs by stating: “This partnership comes within the framework of our belief that the Egyptian, Arab, and African markets are some of the most promising markets at which we are seeking to place our products in the coming period. We are confident that our partnership with Gennecs will be fruitful due to the company’s leadership in the field of pharmaceuticals globally and regionally.”
When it comes to Gennecs Holding’s background, it is important to mention that the company is the medical arm of Dabatco, one of the companies of the Eldaba Holding Group, which has its regional headquarters in Dubai together with a solid footprint in Canada, USA, Egypt, India & Europe. Dabatco Company was established in 1952, as a family company, and has been managing a group of other subsidiary companies and joint ventures operating in the fields of Trade, Real Estate, Food & Beverages, Hospitality, Entertainment, Technology, Communication, Design & Decoration, as well as Innovation in dozens of countries around the world. Their businesses entail the production of original under license and genetically modified medicines, vaccines, nutritional supplements, medical devices, and laboratories’ equipment. In addition, the company is the regional distributor and agent for many biotechnology products.
